Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04064359
• Other study ID #: OBT076-001
• Status: Recruiting
• Phase: Phase 1
• Start date: July 25, 2019
• Est. completion date: December 31, 2027

Study information

• Verified date: February 2024
• Source: Oxford BioTherapeutics Ltd
• Contact: Medical Monitor
• Phone: +44 (0)1235 861770
• Email: OBT076-001[@]oxfordbiotherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.

Description:

Study OBT076-001 is an open-label, Phase I, dose escalation and expansion clinical study of OBT076 in CD205+ve recurrent and/or metastatic solid tumors that are refractory to standard treatments, or for which a standard therapy is not available or not suitable or is no longer effective. The study will consist of four parts: - Part A: Dose escalation - Part B: OBT076 single agent expansion - Part C: Sequential administration of OBT076 and balstilimab - Part D: Combination therapy with concurrent administration of OBT076 and balstilimab Parts A, B, C and D will consist mainly of 3 periods: Screening, Treatment and Follow-up periods. The treatment period with OBT076 consists of 21 days cycles. Approximately 200 patients will be enrolled across Parts A to D.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is = 18 years of age (at the time of signing the ICF) with non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective.

2. Subject has histologically and/or cytologically confirmed solid tumors.

3. Subject with Breast cancer:

1. Subject with hormone-receptor positive (as per local laboratory) recurrent locally advanced or metastatic breast cancer, regardless of HER2 status, must have received at least two prior lines of endocrine therapy in the adjuvant or metastatic setting, either as monotherapy or in combination with targeted therapy

2. Subject with recurrent locally advanced or metastatic non-curative HER2 negative breast cancer (based on most recently analyzed biopsy), HER2 status is defined as per ASCO-CAP guidelines as negative, if in situ hybridization test or IHC status is 0, 1+, or 2+.

3. Subject with triple negative breast cancer are eligible after at least one prior line of cytotoxic chemotherapy in the metastatic setting.

4. Subject with prior adjuvant or neoadjuvant chemotherapy allowed.

4. Subject has received a maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting. Subject who received three up to five prior lines of cytotoxic chemotherapy in the metastatic setting are eligible, if the last administration of cytotoxic chemotherapy was at least 12 weeks prior to Cycle 1 Day 1

5. Subject has tumor that is positive for CD205 antigen by IHC staining

6. Subject has an ECOG performance status of 0-1.

7. Subject has radiological documented measurable disease (i.e., at least 1 measurable lesion as per RECIST Version 1.1).

8. Subject has adequate organ function

9. Subject has adequate bone marrow function

10. Subject understands and voluntarily signs an ICD prior to any study-related assessments/procedures are conducted.

11. Subject is able to adhere to the study visit schedule and other protocol requirements.

12. Subject who is a female of childbearing potential (defined as a sexually mature women, has not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been naturally postmenopausal for at least 12 consecutive months and is using any adequate form of

birth control must:

1. Have a negative pregnancy test within 1 week before first dose of study drug.

2. Use highly effective method(s) of birth control consistently and correctly during the study and for at least 4 months after the last dose of study drug.

3. Agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 4 months after the last dose of study.

4. Agree to no plan to breastfeed and no plan to become pregnant during the study and for at least 4 months after the last dose of study drug.

13. Subject who is a sexually active male must agree to use a condom, not to donate sperm and have no plans to father a child during the study and for at least 4 months after the last dose of study drug.

Exclusion Criteria:

1. Subject has received any chemotherapy within 28 days prior to Cycle 1 Day 1.

2. Subject has received any other systemic anticancer therapy within 28 days or 5 half-lives of Cycle 1 Day 1.

3. Subject has symptomatic visceral crisis requiring chemotherapy per Investigator judgment for non TNBC.

4. Subject with colorectal cancer and pancreatic cancer are not eligible for the study.

5. Subject with peritoneal involvement, i.e., peritoneal carcinomatosis, are not eligible for the study.

6. Subject has not recovered from the acute toxic effects (CTCAE grade = 1) of prior anticancer therapy, radiation, or major surgery/significant trauma (except alopecia or other toxicities not considered a safety risk for the subject at the Investigator's discretion).

7. Subject has had major surgery within 14 days prior to starting study treatment or has not recovered from major side effects.

8. Subject has had radiotherapy = 4 weeks prior to starting study drug.

9. Subject has a history of, or current symptomatic brain metastasis.

10. Subject has any other malignancy within 5 years prior to randomization

11. Subject has a known or suspected hypersensitivity or other contraindication to any excipients used in the manufacture of OBT076.

12. Subject has significant medical condition, laboratory abnormality, or psychiatric illness that would, in the Investigator's judgment, contraindicate patient participation in the study (e.g., history of thromboembolic event, cardiac dysfunction, chronic pancreatitis, chronic active hepatitis)

13. Subject has severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine <7 days before Cycle 1 Day 1

14. Subject has any condition that confounds the ability to interpret data from the study.

15. Subject is lactating or breastfeeding.

16. Subject has a past medical history of or ongoing clinically relevant interstitial lung disease, drug-induced pneumonitis or severe/very severe COPD.

17. Subject has active or chronic corneal disorder or Sjogren's syndrome.

18. Subject has any ongoing skin disorders not controlled by specific treatment.

19. Subject has significant active cardiac disease within the previous 6 months including unstable angina or angina requiring surgical or medical intervention, significant cardiac arrhythmia, or NYHA class 3 or 4 congestive heart failure, or patients with QTc interval >470ms at screening.

20. Subject has a known history or current diagnosis of HIV infection, unless on triple antiviral treatment with undetectable viral load.

21. Subject who is female of childbearing potential

22. Subject who is unable or unwilling to take folic acid or vitamin B12 supplementation.

23. Subject with a history of allogeneic organ transplant.

24. Subject with grade 3 or 4 immune-related adverse reactions during any prior line of checkpoint inhibitor containing therapy. Patients with immune-related thyroiditis controlled with substitution, or prior asymptomatic lipase increases are eligible for the study.

25. Subject with active autoimmune disease or history of autoimmune disease that required systemic treatment within 3 years of the start of study treatment.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• OBT076, a CD205-directed antibody-drug conjugate
Intravenous (IV) infusion of OBT076 every 3 weeks.

Locations

Country	Name	City	State
Belgium	Institut Jules Bordet	Brussels
Belgium	AZ Groeninge	Kortrijk
France	Institut Paoli Calmettes	Marseille
France	GHP Saint-Joseph	Paris
France	Hopital Saint Antoine	Paris
France	Hopital Saint Louis	Paris
France	Centre Eugène Marquis	Rennes
France	ICANS - Institut de cancérologie Strasbourg	Strasbourg
France	Institut Gustave Roussy - IGR	Villejuif
Greece	Metropolitan Hospital	Athens
Greece	Sotiria General Hospital	Athens
Greece	University General Hospital Attikon	Chaidari	Athens
Greece	University General Hospital of Heraklion	Heraklion
Greece	EuroMedica	Thessaloniki
Spain	START Barcelona HM Nou Delfos	Barcelona
Spain	Hospital Universitario Fundacion Jimenez Diaz	Madrid
Spain	University Hospital Marqués de Valdecilla	Santander
United States	St. Elizabeth Healthcare	Edgewood	Kentucky
United States	The State University of Iowa	Iowa City	Iowa
United States	University of Mississippi Medical Center	Jackson	Mississippi
United States	Cedars-Sinai	Los Angeles	California
United States	Columbia University Medical Center	New York	New York
United States	Mayo Clinic	Phoenix	Arizona
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Quantum Santa Fe	Santa Fe	New Mexico
United States	UCLA	Santa Monica	California
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Oxford BioTherapeutics Ltd

Countries where clinical trial is conducted

United States,  Belgium,  France,  Greece,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quantification of Serum Protein	Enzyme-linked Immunosorbant Assay (ELISA)	2 years
Other	Quantification of Peripheral Blood CD205+ Cells	Flow Cytometry	2 years
Other	Quantification of Immune Cells (ICs) in Tumor Microenvironment (TME)	Immunohistochemistry	2 years
Primary	Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)	Assess incidence of all AEs by NCI CTCAE (Version 5) grades 1-5	1 year
Primary	Percentage of subjects with dose-limiting toxicities (DLTs) as assessed by NCI CTCAE (Version 5)	DLTs defined by NCI CTCAE (Version 5) grades 3-4, with exceptions for duration	1 year
Secondary	Clinical Benefit Ratio (CBR)	RECIST, Version 1.1	2 years
Secondary	Overall Response Rate (ORR)	RECIST, Version 1.1	2 years
Secondary	Duration of Response (DoR)	Kaplan-Meier methodology	2 years
Secondary	Progression Free Survival (PFS)	Kaplan-Meier methodology	2 years
Secondary	Overall Survival (OS)	Kaplan-Meier methodology	2 years
Secondary	Area under the Plasma Concentration versus Time Curve (AUC) of OBT076	Statistics including number of subjects (N), mean, standard deviation, CV%, geometric mean, geometric CV%, median, minimum, and maximum will be provided for OBT076	1 year
Secondary	Maximum Plasma Concentration [Cmax] of OBT076	Statistics including number of subjects (N), mean, standard deviation, CV%, geometric mean, geometric CV%, median, minimum, and maximum will be provided for OBT076	1 year
Secondary	Time Taken to Reach the Maximum Plasma Concentration [Tmax] of OBT076	Statistics including number of subjects (N), mean, standard deviation, CV%, geometric mean, geometric CV%, median, minimum, and maximum will be provided for OBT076	1 year
Secondary	Half-Life [T1/2] of OBT076	Statistics including number of subjects (N), mean, standard deviation, CV%, geometric mean, geometric CV%, median, minimum, and maximum will be provided for OBT076	1 year
Secondary	Clearance (CL) of OBT076	Statistics including number of subjects (N), mean, standard deviation, CV%, geometric mean, geometric CV%, median, minimum, and maximum will be provided for OBT076	1 year
Secondary	Volume of Distribution (Vd) of OBT076	Statistics including number of subjects (N), mean, standard deviation, CV%, geometric mean, geometric CV%, median, minimum, and maximum will be provided for OBT076	1 year